| Dear Voornaam
Cancer Research Horizons will again be celebrating our most innovative and enterprising oncology entrepreneurs by hosting our second Innovation and Entrepreneurship Awards. The event will take place on 20 March 2024 at The Law Society, London and that means now is the time to submit your nominations in these five categories:
Early-Career Entrepreneur Woman Entrepreneur New Startup Startup Achievement Further, Faster, Together (Industry-Academia Collaboration) You have until 10 January to enter the competition.
If you’re looking for inspiration, I encourage you to visit the Cancer Research Horizons Annual Review for highlights and stories about the talented winners from last year’s awards.
And when you’re ready to apply, explore the categories and submit a nomination at Innovation & Entrepreneurship Awards 2024 | Cancer Research Horizons.
Kind regards
Iain Foulkes
Executive Director Research & Innovation
CEO Cancer Research Horizons
Cancer Research UK |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
REAL WORLD DATA SHOW LOW RISK NATURE OF DCIS Jelle Wesseling, Esther Lips, Marjanka Schmidt and colleagues have shown a small association between ductal carcinoma in situ (DCIS) size and margin status with risk of developing invasive breast cancer after DCIS in the same breast.
They used patient data from 47,695 women with a diagnosis of DCIS in the Netherlands, UK, and US who had breast surgery often followed by radiotherapy or endocrine treatment, or both.
The results published in the BMJ showed that the 10-year cumulative incidence of ipsilateral invasive breast cancer was 3.2%, and underline the need for new prognostic markers to distinguish between high- and low-risk cases of DCIS.
This is crucial to save women with low-risk DCIS the burden of intensive treatment without any benefit, preserving their quality of life, while not compromising the excellent treatment outcomes presently achieved for women with high-risk DCIS.
This research by the PRECISION Cancer Grand Challenges team provided an opportunity to review current clinical practice using real world data and enables additional analyses of stage and type of invasive breast cancers that developed in a low percentage of patients after treatment for DCIS.
|
|
|---|
|
|---|
|
|
FAIRIFY YOUR DATA WITH NEW DATA WEBINAR SERIES There’s still time to register for Making Data FAIR, the second event in our webinar series on all things research data at 1-2pm on 27 November.
Join us to find out how you can make your data findable, accessible, interoperable and reproducible (FAIR) with data experts Kevin Litchfield (The Francis Crick Institute), Joseph Day (Cancer Research Horizons) and Kasia Kamieniecka (ELIXIR-UK).
You’ll hear from both academic and commercial perspectives on how to enhance the impact of your research via the FAIR principles. |
|
|---|
| BIOLOGICAL INSIGHTS IN CANCER PREVENTION Walid Khaled and Sara Pensa are studying breast tumour initiation at the University of Cambridge. They have identified six putative targets for prevention therapies, and they are testing the efficacy of various compounds in preventing tumour development in mice for a pilot clinical trial.
Elise Rees is a postdoctoral scientist in Kwee Yong’s lab at UCL Cancer Institute. She’s investigating the role of NK cells in smouldering myeloma to optimise strategies to prevent multiple myeloma.
All three were recently funded through our Biology to Prevention award. They discuss how they are using the award to apply biological insights to prevention research. |
|
|---|
|
|---|
|
|
CALL FOR ABSTRACTS - EACR CONGRESS 2024 The European Association for Cancer Research annual congress will be in Rotterdam, Netherlands on 10-13 June, with a wide agenda including modulating the tumour microenvironment, drug resistance and mechanism-based clinical trials.
You can build knowledge, connections, and collaborations across basic, preclinical, and translational cancer research by attending high-quality scientific talks, Meet the Expert sessions, keynote lectures, early-career roundtables and a large industry exhibition.
Submit your abstract by 4 March to get a chance to present your work at the congress. |
|
|---|
|
|---|
|
|
DISCOVER OUR PICK OF THE MOST INNOVATIVE CANCER TECHNOLOGIES AT OUR CANCER TECH CONFERENCE Come along and discover the latest innovative technologies from our 2023 Cancer Tech Accelerator cohort at our Cancer Tech Conference on 16 November, in partnership with Cancer Research Horizons, Roche and Capital Enterprise.
You will learn about these cutting-edge companies that are looking to transform early detection, diagnosis and treatment of cancer. Through the mentoring and personalised support of the Cancer Tech Accelerator, the cohort companies are on the verge of securing further funding.
You will also enjoy an agenda packed with informative and networking sessions, including a keynote by Genentech’s Lélia Delamarre on Pharma-Tech collaboration in cancer research, a Life Science Investor Panel and pitches from cohort companies. |
|
|---|
|
|---|
|
|
| | | Oxford, UK 13 November 2023 |
|
|---|
|
|---|
| | | London, UK 14 November 2023 |
|
|---|
|
|---|
| | | Edinburgh, UK 14 November 2023 |
|
|---|
|
|---|
| | | London, UK 21 November 2023 |
|
|---|
|
|---|
| | | London, UK 29 November 2023 |
|
|---|
|
|---|
| | | Manchester, UK 27 February 2024 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
